Supplementary file



Suppl. Fig. 1: Strategy to measure intracellular cytokines. Two examples of measuring TGFβ-producing $CD4^+$ T cells in CD74-stimulated (**A**) and control-peptipe (**B**) stimulate PBMC from a patient with SpA are depicted as well as matched isotype controls (**C**, for CD74 stimulated cells and **D**, for control-peptide stimulated cells). After doublet and dead cell exclusion and gating on $CD3^+$ lymphocytes (not shown), we selected $CD3^+CD4^+$ cells with subsequent back-gating on $CD3^+CD4^+TGF\beta^+$ cells.



Suppl. Fig. 2. 6 synthetic peptides representing different epitopes of CD74 (**A**) were evaluated for their immunogenicity. Percentages of TNF-α (**B**), IFNγ (**C**), IL-17A (**D**) or TGFβ-producing CD4⁺ T cells (**E**) after incubation of PBMC from patients with axSpA (n=15) with the indicated peptide or recombinant CD74 protein. Responses of every single patient with each of the indicated peptide are depicted.



Suppl. Fig. 3. Intracellular production of TNF-α (**A**), IFNγ (**B**), IL-17A (**C**) or TGFβ by CD4⁺ T cells after incubation with recombinant CD74 in correlation to detection of CD74 autoantibodies in 15 patients with axSpA, whose cells were evaluated for responses against the 6 synthetic peptides (*p<0.05).